HomeAI · summaries
Storia in 13 fonti
Dona da Mounjaro compra empresa que produz antidepressivos por US$ 3,8 bilhões
Eli Lilly adquire AtaiBeckley, que está estudando spray nasal que utiliza alucinógeno
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.
- ·
economictimes.indiatimes.com
Weight-loss drugmaker Lilly nears $1.97 bn AtaiBeckley's acquisition: Report
Eli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant surge following the news of these discussions. The…
- ·
cnbc.com
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
- ·
endpoints.news
Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley
Eli Lilly will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, showing big pharma’s increasing interest in psychedelics.
- ·
milanofinanza.it
Eli Lilly punta sugli psichedelici: acquisirà AtaiBeckley per 2,8 miliardi di dollari | MilanoFinanza News
L’operazione consente al gruppo farmaceutico di mettere le mani su BPL-003, uno spray nasale a base di DMT in fase 3 di sperimentazione per la depressione resistente. Le azioni di…
- ·
statnews.com
Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its neuroscience pipeline.
- ·
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and other mental health issues. The acquisition includes…
- ·
valor.globo.com
Eli Lilly comprará biofarmacêutica voltada a transtornos mentais por US$ 2,8 bilhões
A empresa afirmou que espera concluir a aquisição, que reforça seu portfólio de neurociência, no terceiro trimestre
- ·
forbes.it
Eli Lilly scommette sulla salute mentale: acquisita AtaiBeckley per 2,8 miliardi di dollari
Eli Lilly acquisisce AtaiBeckley per 2,8 miliardi di dollari per sviluppare trattamenti contro la depressione resistente
- ·
axios.com
Eli Lilly agrees to $3.8B psychedelic buy
The AtaiBeckley acquisition would be the largest psychedelic deal to date.
- ·
benzinga.com
AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal - Eli Lilly (NYSE:LLY), AtaiBeckley (N
Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health pipeline.
- ·
www1.folha.uol.com.br
Dona da Mounjaro compra empresa que produz antidepressivos por US$ 3,8 bilhões
Eli Lilly adquire AtaiBeckley, que está estudando spray nasal que utiliza alucinógeno
- ·
Opinião - Marcelo Leite: 'Veneno de sapo' da Eli Lilly apaga centelha psicodélica
Big Pharma investe US$ 2,8 bi para domesticar alterador de consciência 5-MeO-DMT
- ·
oglobo.globo.com
Fabricante do Monjauro fecha acordo de US$ 3,8 bi para comprar empresa de medicamentos psicodélicos
Acordo reforça a presença de longa data da Lilly na área de neurociências, segmento no qual a empresa revolucionou o tratamento da depressão há cerca de três décadas com o…
- ·
The market for psychedelic drugs to treat mental health conditions gets a big buy signal
Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley extends Big Pharma's embrace of a stigmatized class of medications for treating mental health.
- ·
forbes.com
Big Pharma And Psychedelic Medicine: Eli Lilly’s $3.8 Billion Bet
Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion, marks a pivotal moment for psychedelic medicine.